Merck, Eisai Get Europe OK for Lenvima/Keytruda Combination in Two Cancers

- Advertisement -


Colin Kellaher. By

- Advertisement -
- Advertisement -

Merck & Co. and Isai Co. said on Monday that the European Commission has approved the combination of Christian’s Lenvima and Merck’s Keytruda in a pairing indication.

Merck, based in Kenilworth, NJ and Tokyo-based Isai, said the approval includes the combination for first-line treatment of adults with advanced renal cell carcinoma, the most common type of kidney cancer.

- Advertisement -

The companies said the combination is now also approved for adults with advanced or recurrent endometrial cancer who have disease progression on prior treatment with platinum-containing therapy in any setting or who are not candidates for palliative surgery or radiation.

In March 2018, Christian and Merck formed a collaboration to jointly develop, manufacture and commercialize Lenvima as monotherapy and in combination with Merck’s blockbuster cancer drug Keytruda.

Write to Colin Kellaher at [email protected]

,

- Advertisement -

Stay on top - Get the daily news in your inbox

DMCA / Correction Notice

Recent Articles

Related Stories

Stay on top - Get the daily news in your inbox